Detection of Lung Cancer by Plasma Lipids

Study Overview
=================
Brief Summary
-----------------
There are no reliable blood-based tests currently available for early-stage lung cancer diagnosis. We try to establish a highly accurate method for detecting early-stage lung cancer by combining machine learning with untargeted and targeted metabolomics .

Detailed Description
-----------------
All plasma lipids were first detected by untargeted metabolomics methods and 9 feature lipids of early-stage lung cancer were selected by support vector machine algorithm. Then, a targeted metabolomics method was developed to detect the 9 lipids quantitatively based on multiple reaction monitoring mode. Finally, a detection model was established based on the 9 lipids.

Official Title
-----------------
Detection of Early-stage Lung Cancer Using Machine Learning and Plasma Metabolomics

Conditions
-----------------
Early-Stage Lung Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: Plasma lipids


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pulmonary nodules or opacity plan to receive surgery Exclusion Criteria: history of other malignancies received anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants received surgery<br>Patients who underwent surgery at the Department of Thoracic Surgery of Peaking University People's Hospital, Jiangsu Cancer Hospital, and Beijing Haidian Hospital were enrolled with the following criteria: 1) pathologically confirmed lung cancer; 2) no history of other malignancies; 3) no anti-cancer treatment (chemotherapy, radiotherapy, targeted therapy, etc.) before surgery. Plasma samples were collected before surgery and plasma lipids were detected by mass spectrometry. Pathological diagnosis and clinical characteristics of enrolled participants were retrieved. | Diagnostic Test: Plasma lipids<br>* Plasma lipids were detected by an Ultimate 3000 ultra-high-performance liquid chromatography (UHPLC) system coupled with Q-Exactive MS (Thermo Scientific) . Then a detection model was built based on plasma lipids using machine learning algorithm.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma Lipids | A detection model based on 9 lipids were developed, including 3 lysophosphatidylcholines, 5 phosphatidylcholines, and a triglyceride. The 9 lipids were detected by targeted metabolomics by mass spectrometry. | All samples were detected together after participants recruitment and sample collection. All samples were detected within 18 months from sample collection. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Early-Stage Lung Cancer, Plasma Metabolomics, Lipids, Machine Learning